Document:

<PAGE>
                                                                    EXHIBIT 10.5

THIS WARRANT AND ANY SECURITIES ACQUIRED UPON THE EXERCISE OF THIS WARRANT HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY
APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD, OR OTHERWISE
TRANSFERRED, PLEDGED, OR HYPOTHECATED UNLESS AND UNTIL SUCH SECURITIES ARE
REGISTERED UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR AN OPINION,
SATISFACTORY TO THE COMPANY, OF COUNSEL IS OBTAINED TO THE EFFECT THAT SUCH
REGISTRATION IS NOT REQUIRED.

                VOID AFTER 5:00 P.M. EASTERN TIME, JUNE 30, 2006

                                    WARRANT

                              FOR THE PURCHASE OF

                         50,000 SHARES OF COMMON STOCK

                                       OF

                         HORIZON MEDICAL PRODUCTS, INC.

1.       Warrant.

         THIS CERTIFIES THAT, in consideration of $10.00 and other good and
valuable consideration, duly paid by or on behalf of Lippert/Heilshorn &
Associates, Inc. ("Holder"), as registered owner of this Warrant, to Horizon
Medical Products, Inc. ("Company"), Holder is entitled, at any time or from
time to time on or after June 30, 2003 ("Commencement Date"), and at or before
5:00 p.m., Eastern Time June 30, 2006 ("Expiration Date"), but not thereafter,
to subscribe for, purchase and receive, in whole or in part, up to fifty
thousand (50,000) shares of Common Stock of the Company, $0.001 par value
("Common Stock"). If the Expiration Date is a day on which banking institutions
are authorized by law to close, then this Warrant may be exercised on the next
succeeding day which is not such a day in accordance with the terms herein.
During the period ending on the Expiration Date, the Company agrees not to take
any action that would terminate the Warrant. This Warrant is initially
exercisable at sixty-nine cents ($0.69) per share of Common Stock purchased;
provided, however, that upon the occurrence of any of the events specified in
Section 5 hereof, the rights granted by this Warrant, including the exercise
price and the number of shares of Common Stock to be received upon such
exercise, shall be adjusted as therein specified. The term "Exercise Price"
shall mean the initial exercise price or the adjusted exercise price, depending
on the context, of a share of Common Stock. The term "Securities" shall mean
the shares of Common Stock issuable upon exercise of this Warrant.

2.       Exercise.

         2.1      Exercise Form. In order to exercise this Warrant, the
exercise form attached hereto must be duly executed and completed and delivered
to the Company, together with this Warrant and payment of the Exercise Price
for the Securities being purchased. If the subscription rights represented
hereby shall not be exercised at or before 5:00 p.m., Eastern time, on the
Expiration Date, this Warrant shall become and be void without further force or
effect, and all rights represented hereby shall cease and expire.

<PAGE>

         2.2      Legend. Each certificate for Securities purchased under this
Warrant shall bear a legend as follows, unless such Securities have been
registered under the Securities Act of 1933, as amended ("Act"):

                  THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
                  REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR
                  ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE OFFERED,
                  SOLD, OR OTHERWISE TRANSFERRED, PLEDGED, OR HYPOTHECATED
                  UNLESS AND UNTIL SUCH SECURITIES ARE REGISTERED UNDER SUCH
                  ACT AND APPLICABLE STATE SECURITIES LAWS OR AN OPINION,
                  SATISFACTORY TO THE COMPANY, OF COUNSEL IS OBTAINED TO THE
                  EFFECT THAT SUCH REGISTRATION IS NOT REQUIRED.

          2.3     Conversion Right.

                  2.3.1 Determination of Amount. In lieu of the payment of the
Exercise Price in cash, the Holder shall have the right (but not the
obligation) to convert this Warrant, in whole or in part, into Common Stock
("Conversion Right"), as follows: upon exercise of the Conversion Right, the
Company shall deliver to the Holder (without payment by the Holder of any of
the Exercise Price) that number of shares of Common Stock equal to the quotient
obtained by dividing (x) the "Value" (as defined below) of the portion of the
Warrant being converted at the time the Conversion Right is exercised by (y)
the Market Price on the date of conversion. The "Value" of the portion of the
Warrant being converted shall equal the remainder derived from subtracting (a)
the Exercise Price multiplied by the number of shares of Common Stock being
converted from (b) the Market Price of the Common Stock on the date of
conversion multiplied by the number of shares of Common Stock being converted.
As used herein, the term "Market Price" at any date shall be deemed to be the
last reported sale price of the Common Stock on such date, or, in case no such
reported sale takes place on such day, the average of the last reported sales
prices for the immediately preceding three trading days, in either case as
officially reported by the principal securities exchange on which the Common
Stock is listed or admitted to trading, or, if the Common Stock is not listed
or admitted to trading on any national securities exchange or if any such
exchange on which the Common Stock is listed is not its principal trading
market, the last reported sale price as furnished by the National Association
of Securities Dealers, Inc. ("NASD") through the NASDAQ National Market or
SmallCap Market, or, if applicable, the OTC Bulletin Board, or if the Common
Stock is not listed or admitted to trading on any of the foregoing markets, or
similar organization, as determined in good faith by resolution of the Board of
Directors of the Company, based on the best information available to it.

                  2.3.2 Exercise of Conversion Right. The Conversion Right may
be exercised by the Holder on any business day on or after the Commencement
Date and not later than the Expiration Date by delivering the Warrant with a
duly executed exercise form attached hereto with the conversion section
completed to the Company, exercising the Conversion Right and specifying the
total number of shares of Common Stock the Holder will purchase pursuant to
such conversion.

 3.      Transfer.

         3.1      Transferability. Subject to the provisions of this Section 3,
this Warrant and all rights hereunder are transferable, in whole or in part,
upon surrender of this Warrant with a properly executed assignment (in the form
attached hereto) at the principal office of the Company, but only after the
Company's prior written consent to such transfer.

         3.2      Representations of Holder. By accepting this Warrant, the
Holder represents and warrants to the Company as follows:

                                      -2-
<PAGE>

                  (a) The Warrant and the Securities issuable upon exercise of
this Warrant will be acquired for investment for the Holder's own account and
not with a view to the sale or distribution of any part thereof, and the Holder
has no present intention of selling or engaging in any public distribution of
the same except pursuant to a registration or exemption from the Securities Act
of 1933, as amended ("Securities Act").

                  (b) The Holder understands and acknowledges (i) that the
Securities issuable upon exercise of the Holder's rights contained herein are
not registered under the Securities Act or qualified under applicable state
securities laws because the issuance contemplated by this Warrant will be
exempt from the registration and qualification requirements thereof, and (ii)
that the Company's reliance on such exemption is predicated on the accuracy of
the representations set forth in this Section 3.2.

                  (c) The Holder has such knowledge and experience in financial
and business matters as to be capable of evaluating the merits and risks of its
investment and has the ability to bear the economic risks of its investment.

                  (d) The Holder understands that if the Company's Common Stock
ceases to be registered with the Securities and Exchange Commission pursuant to
paragraph 12 of the Securities Exchange Act of 1934 (the "Exchange Act"), or if
the Company ceases to file the reports required under the Exchange Act, or if a
registration statement covering the securities under the Securities Act is not
in effect when it desires to resell (i) this Warrant or (ii) the Securities
issuable upon exercise of this Warrant, it may be required to hold such
securities for an indefinite period. The Holder is aware of the provisions of
Rule 144 promulgated under the Securities Act.

                  (e) The Holder will not offer, sell, or otherwise dispose of
this Warrant or any Securities to be issued upon exercise hereof except under
circumstances that will not result in a violation of the Securities Act or any
state securities laws.

                  (f) Upon exercise of this Warrant, the Holder shall, if
requested by the Company, confirm in writing, in a form satisfactory to the
Company, that the Warrant shares so purchased are being acquired solely for the
Holder's own account and not as a nominee for any other party, for investment,
and not with a view toward distribution or resale.

         3.3      Securities Law Matters. This Warrant and the Securities may
not be sold or transferred unless either (i) they first shall have been
registered under the Securities Act, or (ii) if requested by the Company, the
Company first shall have been furnished with an opinion of legal counsel,
reasonably satisfactory to the Company, to the effect that such sale or
transfer is exempt from the registration requirements of the Act.
Notwithstanding the foregoing, no registration or opinion of counsel shall be
required for a sale or transfer made in accordance with Rule 144 under the Act
provided that the Company shall have been furnished with such information as
the Company may reasonably request to provide reasonable assurance that the
requirements of Rule 144 have been satisfied.

4.       New Warrants to be Issued.

         4.1      Partial Exercise or Transfer. Subject to the restrictions in
Section 3 hereof, this Warrant may be exercised or assigned in whole or in
part. In the event of the exercise or assignment hereof in part only, upon
surrender of this Warrant for cancellation, together with the duly executed
exercise or assignment form and funds (or conversion equivalent) sufficient to
pay any Exercise Price and/or transfer tax, the Company shall cause to be
delivered to the Holder without charge a new Warrant of like tenor to this
Warrant in the name of the Holder evidencing

                                      -3-
<PAGE>
the right of the Holder to purchase the aggregate number of shares of Common
Stock and Warrants purchasable hereunder as to which this Warrant has not been
exercised or assigned.

         4.2      Lost Certificate. Upon receipt by the Company of evidence
satisfactory to it of the loss, theft, destruction, or mutilation of this
Warrant and of reasonably satisfactory indemnification, the Company shall
execute and deliver a new Warrant of like tenor and date. Any such new Warrant
executed and delivered as a result of such loss, theft, mutilation, or
destruction shall constitute a substitute contractual obligation on the part of
the Company.

5.       Adjustments.

         5.1      Adjustments to Exercise Price and Number of Securities. The
Exercise Price and the number of shares of Common Stock underlying this Warrant
shall be subject to adjustment from time to time as hereinafter set forth:

                  5.1.1 Stock Dividends -- Recapitalization, Reclassification,
Split-Ups. If, after the date hereof, and subject to the provisions of Section
5.2 below, the number of outstanding shares of Common Stock is increased by a
stock dividend on the Common Stock payable in shares of Common Stock or by a
split-up, recapitalization, or reclassification of shares of Common Stock or
other similar event, then, on the effective date thereof, the number of shares
of Common Stock issuable on exercise of this Warrant shall be increased in
proportion to such increase in outstanding shares.

                  5.1.2 Aggregation of Shares. If after the date hereof, and
subject to the provisions of Section 5.2, the number of outstanding shares of
Common Stock is decreased by a consolidation, combination, or reclassification
of shares of Common Stock or other similar event, then, upon the effective date
thereof, the number of shares of Common Stock issuable on exercise of this
Warrant shall be decreased in proportion to such decrease in outstanding
shares.

                  5.1.3 Adjustments in Exercise Price. Whenever the number of
shares of Common Stock purchasable upon the exercise of this Warrant is
adjusted, as provided in this Section 5.1, the Exercise Price shall be adjusted
(to the nearest cent) by multiplying such Exercise Price immediately prior to
such adjustment by a fraction (x), the numerator of which shall be the number
of shares of Common Stock purchasable upon the exercise of this Warrant
immediately prior to such adjustment, and (y) the denominator of which shall be
the number of shares of Common Stock so purchasable immediately thereafter.

                  5.1.4 Replacement of Securities Upon Reorganization, etc. In
case of any reclassification or reorganization of the outstanding shares of
Common Stock other than a change covered by Section 5.1.1 hereof or which
solely affects the par value of such shares of Common Stock, or in the case of
any merger or consolidation of the Company with or into another corporation
(other than a consolidation or merger in which the Company is the continuing
corporation and which does not result in any reclassification or reorganization
of the outstanding shares of Common Stock), or in the case of any sale or
conveyance to another corporation or entity of the property of the Company as
an entirely or substantially as an entirety in connection with which the
Company is dissolved, the Holder of this Warrant shall have the right
thereafter (until the expiration of the right of exercise of this Warrant) to
receive upon the exercise hereof, for the same aggregate Exercise Price payable
hereunder immediately prior to such event, the kind and amount of shares of
stock or other securities or property (including cash) receivable upon such
reclassification, reorganization, merger, or consolidation, or upon a
dissolution following any such sale or other transfer, by a Holder of the
number of shares of Common Stock of the Company obtainable upon exercise of
this Warrant immediately prior to such event; and if any reclassification also
results in a change in shares of Common Stock covered by Section 5.1.1 or
5.1.2, then such adjustment shall be made pursuant to Sections 5.1.1, 5.1.2,
5.1.3, and this

                                      -4-
<PAGE>

Section 5.1.4. The provisions of this Section 5.1.4 shall similarly apply to
successive reclassifications, reorganizations, mergers or consolidations,
sales, or other transfers.

                  5.1.5 Changes in Form of Warrant. This form of Warrant need
not be changed because of any change pursuant to this Section, and Warrants
issued after such change may state the same Exercise Price and the same number
of shares of Common Stock and Warrants as are stated in the Warrants initially
issued pursuant to this Agreement. The acceptance by any Holder of the issuance
of new Warrants reflecting a required or permissive change shall not be deemed
to waive any rights to a prior adjustment or the computation thereof.

         5.2      Elimination of Fractional Interests. The Company shall not be
required to issue certificates representing fractions of shares of Common Stock
upon the exercise of this Warrant, nor shall it be required to issue scrip or
pay cash in lieu of any fractional interests, it being the intent of the
parties that all fractional interests shall be eliminated by rounding any
fraction up to the nearest whole number of shares of Common Stock or other
securities, properties, or rights.

6.       Reservation and Listing.

         The Company shall at all times reserve and keep available out of its
authorized shares of Common Stock, solely for the purpose of issuance upon
exercise of this Warrant, such number of shares of Common Stock or other
securities, properties, or rights as shall be issuable upon the exercise
thereof. The Company covenants and agrees that, upon exercise of the Warrants
and payment of the Exercise Price therefor, all shares of Common Stock and
other securities issuable upon such exercise shall be duly and validly issued,
fully paid, and non-assessable and not subject to preemptive rights of any
stockholder. Upon exercise of the Warrant and payment of the Exercise Price
therefor and thereafter, the Company shall use its best efforts to cause all
shares of Common Stock issuable upon exercise of the Warrants to be listed
(subject to official notice of issuance) on all securities exchanges (or, if
applicable on NASDAQ) on which the Common Stock is then listed and/or quoted.

7.       Certain Notice Requirements.

         7.1      Holder's Right to Receive Notice. Nothing herein shall be
construed as conferring upon the Holder the right to vote or consent or to
receive notice as a stockholder for the election of directors or any other
matter, or as having any rights whatsoever as a stockholder of the Company. If,
however, at any time prior to the expiration of the Warrants and their
exercise, any of the events described in Section 7.2 shall occur, then, in one
or more of said events, the Company shall give written notice of such event at
least fifteen days prior to the date fixed as a record date or the date of
closing the transfer books for the determination of the stockholders entitled
to such dividend, distribution, conversion, or exchange of securities or
subscription rights, or entitled to vote on such proposed dissolution,
liquidation, winding up, or sale. Such notice shall specify such record date or
the date of the closing of the transfer books, as the case may be.

         7.2      Events Requiring Notice. The Company shall be required to
give the notice described in this Section 7 upon one or more of the following
events: (i) if the Company shall take a record of the holders of its shares of
Common Stock for the purpose of entitling them to receive a dividend or
distribution, or (ii) the Company shall offer to all the holders of its Common
Stock any additional shares of capital stock of the Company or securities
convertible into or exchangeable for shares of capital stock of the Company, or
any option, right, or warrant to subscribe therefor, or (iii) a merger or
reorganization in which the Company is not the surviving party, or (iv) a
dissolution, liquidation, or winding up of the Company (other than in
connection with a consolidation or merger) or a sale of all or substantially
all of its property, assets, and business shall be proposed.

                                      -5-
<PAGE>

         7.3      Notice of Change in Exercise Price. The Company shall,
promptly after an event requiring a change in the Exercise Price pursuant to
Section 5 hereof, send notice to the Holder of such event and change ("Price
Notice"). The Price Notice shall describe the event causing the change and the
method of calculating same and shall be certified as being true and accurate by
the Company's President and Chief Financial Officer.

         7.4      Transmittal of Notices. All notices, requests, consents, and
other communications under this Warrant shall be in writing and shall be deemed
to have been duly made on the date of delivery if delivered personally or sent
by overnight courier, with acknowledgement of receipt by the party to which
notice is given, or the fifth day after mailing if mailed to the party to whom
notice is to be given, by registered or certified mail, return receipt
requested, postage prepaid, and properly addressed as follows: (i) if to the
registered Holder of this Warrant, to the address of such Holder as shown on
the books of the Company, or (ii) if to the Company, to its principal office.

8.       Miscellaneous.

         8.1      Headings. The headings contained herein are for the sole
purpose of convenience of reference, and shall not in any way limit or affect
the meaning or interpretation of any of the terms or provisions of this
Warrant.

         8.2      Entire Agreement. This Warrant (together with the other
agreements and documents being delivered pursuant to or in connection with this
Warrant) constitutes the entire agreement of the parties hereto with respect to
the subject matter hereof, and supersedes all prior agreements and
understandings of the parties, oral and written, with respect to the subject
matter hereof.

         8.3      Binding Effect. This Warrant shall inure solely to the
benefit of and shall be binding upon, the Holder and the Company and their
respective successors, legal representatives, and assigns, and no other person
shall have or be construed to have any legal or equitable right, remedy, or
claim under or in respect of or by virtue of this Warrant or any provisions
herein contained.

         8.4      Governing Law; Submission to Jurisdiction. This Warrant shall
be governed by and construed and enforced in accordance with the laws of the
State of Georgia, without giving effect to conflict of laws. The Company hereby
agrees that any action, proceeding, or claim against it arising out of, or
relating in any way to this Warrant shall be brought and enforced in the courts
of the State of Georgia or of the United States of America in a district court
located in the State of Georgia, and irrevocably submits to such jurisdiction,
which jurisdiction shall be exclusive. The Company hereby waives any objection
to such exclusive jurisdiction and that such courts represent an inconvenient
forum. Any process or summons to be served upon the Company may be served by
transmitting a copy thereof by registered or certified mail, return receipt
requested, postage prepaid, addressed to it at the address set forth in Section
7 hereof. Such mailing shall be deemed personal service and shall be legal and
binding upon the Company in any action, proceeding, or claim.

         8.5      Waiver, etc. The failure of the Company or the Holder to at
any time enforce any of the provisions of this Warrant shall not be deemed or
construed to be a waiver of any such provision, nor to in any way affect the
validity of this Warrant or any provision hereof or the right of the Company or
any Holder to thereafter enforce each and every provision of this Warrant. No
waiver of any breach, non-compliance, or non-fulfillment of any of the
provisions of this Warrant shall be effective unless set forth in a written
instrument executed by the party or parties against whom or which enforcement
of such waiver is sought; and no waiver of any such breach, non-

                                      -6-
<PAGE>

compliance, or non-fulfillment shall be construed or deemed to be a waiver of
any other or subsequent breach, non-compliance, or non-fulfillment.

         8.6      Exchange Agreement. As a condition of the Holder's receipt
and acceptance of this Warrant, the Holder agrees that, at any time prior to
the complete exercise of this Warrant by the Holder, if the Company and
Lippert/Heilshorn & Associates, Inc. enter into an agreement ("Exchange
Agreement") pursuant to which they agree that all outstanding Warrants will be
exchanged for securities or cash or a combination of both, then the Holder
shall agree to such exchange and become a party to the Exchange Agreement.

         IN WITNESS WHEREOF, the Company has caused this Warrant to be signed
by its duly authorized officer as of the 17th day of June, 2003.

                                      HORIZON MEDICAL PRODUCTS, INC.

                                      By: /s/ William E. Peterson, Jr.
                                       -----------------------------------------
                                             William E. Peterson, Jr., President

                                      -7-<PAGE>
                                                                    Exhibit 10.6

                          AMENDMENT TO PROMISSORY NOTE

         THIS AMENDMENT, made and entered into as of July 15, 2003, by and
between Horizon Medical Products, Inc., a Georgia corporation ("Horizon"), and
Roy C. Mallady, Jr. ("Mallady");

         WHEREAS, Mallady has delivered his Promissory Note dated September 28
1995 payable to Horizon in the principal amount of Seventy Seven Thousand Six
Hundred Twelve and 43/100 Dollars ($77,612.43) (the "Note"), as amended by
Amendment to Promissory Note dated September 28, 1996;

         WHEREAS, Horizon has agreed with Mallady to change the payment terms
for the Note as provided herein;

         NOW, THEREFORE, in consideration of Ten Dollars ($10.00) paid and other
good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties agree to amend the Note, as follows:

          1. The entire unpaid principal of Seventy Seven Thousand Six Hundred
Twelve and 43/100 Dollars ($77,612.43) and all accrued and unpaid interest prior
to the date hereof in the amount of Forty Thousand One Hundred Seventy and
No/100 Dollars ($40,170.00) shall be payable in twelve (12) monthly
installments, commencing on July 15, 2003 and on the 15th day of each month
thereafter until paid in full, according to the amortization schedule attached
hereto and incorporated herein by this reference. Interest shall accrue from the
date hereof on the unpaid principal only at the simple rate of eight percent
(8%) per annum and shall be payable in twelve (12) monthly payments on the same
dates as each monthly payment of principal is payable, as provided in the
attached amortization schedule. The total monthly payments for the two preceding
sentences are reflected in "Combined Note 2" in the attached schedule.

          2. Other than the amendment described above, all other provisions of
the Note shall continue in full force and effect. This amendment shall be
binding upon and inure to the benefit of the parties hereto and their personal
representatives, successors, and assigns.

         WITNESS, the execution of the undersigned effective as of the date
first set forth above.

                                           HORIZON MEDICAL PRODUCTS, INC.

                                           By: /s/ Robert Wenzel
                                              ----------------------------------

                                           Title: President
                                                  ------------------------------

                                           /s/Roy C. Mallady, Jr.
                                           -------------------------------------
                                           Roy C. Mallady, Jr.

<PAGE>

                    Schedule to Amendment to Promissory Note

REPAYMENT OF PRINCIPAL OF $77,612 NOTE DATED 09/26/95.
NOTE 2

<TABLE>
<CAPTION>
                      Principal     Interest      Mo pymt
                      ---------     --------     --------
   <S>           <C>  <C>           <C>          <C>             <C>
                                                                 77,612.00  Principal balance
    7/15/2003    1    6,232.59      517.41       6,750.00        71,379.41
    8/15/2003    2    6,274.14      475.86       6,750.00        65,105.28
    9/15/2003    3    6,315.96      434.04       6,750.00        58,789.31
   10/15/2003    4    6,358.07      391.93       6,750.00        52,431.24
   11/15/2003    5    6,400.46      349.54       6,750.00        46,030.78
   12/15/2003    6    6,443.13      306.87       6,750.00        39,587.65
    1/15/2004    7    6,486.08      263.92       6,750.00        33,101.57
    2/15/2004    8    6,529.32      220.68       6,750.00        26,572.25
    3/15/2004    9    6,572.85      177.15       6,750.00        19,999.40
    4/15/2004   10    6,616.67      133.33       6,750.00        13,382.73
    5/15/2004   11    6,660.78       89.22       6,750.00         6,721.94
    6/15/2004   12    6,721.95       44.81       6,766.76            (0.00)

                     77,612.00    3,404.76
</TABLE>

REPAYMENT OF ACCRUED INTEREST ON NOTE 2.

<TABLE>
<CAPTION>
                          Principal   Interest    Mo pymt
                          ---------   --------   --------
    <S>            <C>    <C>         <C>         <C>            <C>
                                                                 40,170.00  Principal balance
     7/15/2003     1      3,347.50      0.00     3,347.50        36,822.50
     8/15/2003     2      3,347.50      0.00     3,347.50        33,475.00
     9/15/2003     3      3,347.50      0.00     3,347.50        30,127.50
    10/15/2003     4      3,347.50      0.00     3,347.50        26,780.00
    11/15/2003     5      3,347.50      0.00     3,347.50        23,432.50
    12/15/2003     6      3,347.50      0.00     3,347.50        20,085.00
     1/15/2004     7      3,347.50      0.00     3,347.50        16,737.50
     2/15/2004     8      3,347.50      0.00     3,347.50        13,390.00
     3/15/2004     9      3,347.50      0.00     3,347.50        10,042.50
     4/15/2004    10      3,347.50      0.00     3,347.50         6,695.00
     5/15/2004    11      3,347.50      0.00     3,347.50         3,347.50
     6/15/2004    12      3,347.50      0.00     3,347.50             0.00

                         40,170.00      0.00
</TABLE>

<PAGE>

COMBINED NOTE 2

<TABLE>
<CAPTION>
                         Principal     Interest      Mo pymt
                         ---------    ---------     ---------
    <S>          <C>     <C>          <C>           <C>            <C>
                                                                   117,782.00  Principal balance
     7/15/2003    1       9,580.09      517.41      10,097.50      108,201.91
     8/15/2003    2       9,621.64      475.86      10,097.50       98,580.28
     9/15/2003    3       9,663.46      434.04      10,097.50       88,916.81
    10/15/2003    4       9,705.57      391.93      10,097.50       79,211.24
    11/15/2003    5       9,747.96      349.54      10,097.50       69,463.28
    12/15/2003    6       9,790.63      306.87      10,097.50       59,672.65
     1/15/2004    7       9,833.58      263.92      10,097.50       49,839.07
     2/15/2004    8       9,876.62      220.68      10,097.50       39,962.25
     3/15/2004    9       9,920.35      177.15      10,097.50       30,041.90
     4/15/2004   10       9,964.17      133.33      10,097.50       20,077.73
     5/15/2004   11      10,008.28       89.22      10,097.50       10,069.44
     6/15/2004   12      10,069.45       44.81      10,097.50           (0.00)

                        117,782.00    3,404.76
</TABLE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}]]